Novo Nordisk presents key findings from semaglutide trials at ADA scientific sessions 2024

FHS
June 22, 2024
6:45 am

Novo Nordisk today announced the presentation of 34 abstracts highlighting the breadth of its portfolio at the upcoming 84th Scientific Sessions of the American Diabetes Association (ADA).

Roche’s Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 7, 2024

Alnylam reports growth in sales of rare disease treatments

Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the

August 3, 2023

Frontier Airlines flight attendants vote to authorize strike – The Cannabist

Frontier Airlines flight attendants voted to authorize a strike over a business model change they say has resulted in less pay, the Association of Flight

September 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.